华夏创新医药龙头混合C(012982)资产负债表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 资产 |
| 银行存款 |
- |
- |
- |
- |
| 结算备付金 |
1,184,046.45 |
2,597,738.27 |
587,301.51 |
217,113.35 |
| 存出保证金 |
217,941.73 |
130,979.88 |
87,999.37 |
87,614.66 |
| 交易性金融资产 |
189,601,933.12 |
194,833,406.17 |
129,615,494.44 |
145,221,627.07 |
| 其中:股票投资 |
189,601,933.12 |
194,833,406.17 |
129,615,494.44 |
145,221,627.07 |
| 债券投资 |
- |
- |
- |
- |
| 资产支持证券投资 |
- |
- |
- |
- |
| 衍生金融资产 |
- |
- |
- |
- |
| 买入返售金融资产 |
- |
- |
- |
- |
| 应收证券清算款 |
3,611,088.36 |
1,499,120.15 |
1,295,550.70 |
2,162,669.71 |
| 应收利息 |
- |
- |
- |
- |
| 应收股利 |
- |
160,221.64 |
- |
74,501.84 |
| 应收申购款 |
1,751,383.63 |
532,248.26 |
47,599.89 |
264,191.68 |
| 其他资产 |
- |
- |
- |
- |
| 资产总计 |
223,660,496.99 |
220,798,083.58 |
155,526,976.20 |
163,397,611.66 |
| 负 债 |
| 短期借款 |
- |
- |
- |
- |
| 交易性金融负债 |
- |
- |
- |
- |
| 衍生金融负债 |
- |
- |
- |
- |
| 卖出回购金融资产款 |
- |
- |
- |
- |
| 应付证券清算款 |
4,548,402.95 |
4,319,000.77 |
2,570,058.54 |
- |
| 应付赎回款 |
5,429,518.63 |
3,528,159.87 |
413,162.98 |
379,343.42 |
| 应付管理人报酬 |
237,187.19 |
213,365.42 |
164,037.70 |
166,140.42 |
| 应付托管费 |
39,531.20 |
35,560.91 |
27,339.60 |
27,690.07 |
| 应付销售服务费 |
60,768.16 |
56,990.77 |
43,387.93 |
46,145.78 |
| 应付交易费用 |
- |
- |
- |
- |
| 应交税费 |
- |
- |
- |
- |
| 应付利息 |
- |
- |
- |
- |
| 应付利润 |
- |
- |
- |
- |
| 其他负债 |
820,186.50 |
581,766.07 |
1,255,197.75 |
2,149,032.44 |
| 负债合计 |
11,135,594.63 |
8,734,843.81 |
4,473,184.50 |
2,768,352.13 |
| 所有者权益 |
| 实收基金 |
251,026,023.87 |
242,981,853.79 |
249,309,055.26 |
266,630,053.87 |
| 未分配利润 |
-38,501,121.51 |
-30,918,614.02 |
-98,255,263.56 |
-106,000,794.34 |
| 所有者权益合计 |
212,524,902.36 |
212,063,239.77 |
151,053,791.70 |
160,629,259.53 |
| 负债及所有者权益总计 |
223,660,496.99 |
220,798,083.58 |
155,526,976.20 |
163,397,611.66 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年